The ERBB network: at last, cancer therapy meets systems biology

Yosef Yarden; Gur Pines

doi:10.1038/nrc3309

This Timeline article focuses on the ERBB network of receptor tyrosine kinases, which exemplifies how a constant dialogue between basic and clinical cancer research can lead to the development of both novel drugs and strategies to overcome acquired resistance.

Loading next page...

References (212)

M. Alimandi, A. Romano, M. Curia, R. Muraro, P. Fedi, S. Aaronson, P. Fiore, M. Kraus (1995)
Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas.
Oncogene, 10 9
P. Fiore, J. Pierce, T. Fleming, R. Hazan, A. Ullrich, C. King, J. Schlessinger, S. Aaronson (1987)
Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cells
Cell, 51
(2003)
The ErbB 2 ErbB 3 heterodimer functions as an oncogenic unit : ErbB 2 requires ErbB 3 to drive breast tumor cell proliferation
Nature Reviews Cancer, 3
S Cohen (1957)
15
Cancer Res., 17
GN Hortobagyi (2005)
Trastuzumab in the treatment of breast cancer
N. Engl. J. Med., 353
M. Robinson, K. Hodge, E. Horak, A. Sundberg, M. Russeva, C. Shaller, M. Mehren, I. Shchaveleva, H. Simmons, J. Marks, G. Adams (2008)
Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro
British Journal of Cancer, 99
S. Bamford, E. Dawson, S. Forbes, J. Clements, Roger Pettett, A. Doğan, A. Flanagan, J. Teague, P. Futreal, Michael Stratton, R. Wooster (2004)
The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website
British Journal of Cancer, 91
J. Baselga, I. Bradbury, H. Eidtmann, S. Cosimo, E. Azambuja, C. Aura, H. Gómez, P. Dinh, K. Fauria, V. Dooren, G. Aktan, A. Goldhirsch, Tsai-Wang Chang, Z. Horváth, M. Coccia-Portugal, J. Dômont, L. Tseng, G. Kunz, J. Sohn, V. Semiglazov, G. Lerzo, M. Pálácova, V. Probachai, L. Pusztai, M. Untch, R. Gelber, M. Piccart-Gebhart (2012)
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
The Lancet, 379
J. Baselga, I. Bradbury, H. Eidtmann, S. Cosimo, C. Aura, H. Gómez, P. Dinh, K. Fauria, V. Dooren, G. Aktan, Z. Horváth, J. Dômont, L. Tseng, G. Kunz, V. Semiglazov, G. Lerzo, M. Pálácova, V. Probachai, L. Pusztai, M. Untch, R. Gelber (2012)
Lapatinib with trastuzumab for HER 2-positive early breast cancer ( NeoALTTO ) : a randomised , open-label , multicentre , phase 3 trial
T. Junttila, R. Akita, Kathryn Parsons, Carter Fields, Gail Phillips, L. Friedman, D. Sampath, M. Sliwkowski (2009)
Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.
Cancer cell, 15 5
T. Garrett, N. Mckern, M. Lou, T. Elleman, T. Adams, G. Lovrecz, M. Kofler, R. Jorissen, E. Nice, A. Burgess, C. Ward (2003)
The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors.
Molecular cell, 11 2
G. Todaro, J. Larco, Stanley Cohen (1976)
Transformation by murine and feline sarcoma viruses specifically blocks binding of epidermal growth factor to cells
Nature, 264
Hawoong Jeong, S. Mason, A. Barabási, Z. Oltvai (2001)
Lethality and centrality in protein networks
Nature, 411
F. Fiore, F. Blanchard, F. Charbonnier, F. Pessot, A. Lamy, M. Galais, L. Bastit, Audrey Killian, Richard Sesboüé, Jean-Jacques Tuech, A. Queuniet, B. Paillot, Jean-Christophe Sabourin, Francis Michot, Pierre Michel, Thierry Frebourg (2007)
Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy
British Journal of Cancer, 96
R. Schweitzer, R. Schweitzer, B. Shilo (1997)
A thousand and one roles for the Drosophila EGF receptor.
Trends in genetics : TIG, 13 5
Y. Yarden, J. Schlessinger (2008)
The EGF receptor kinase: evidence for allosteric activation and intramolecular self-phosphorylation.
Ciba Foundation symposium, 116
T. Libermann, Harris Nusbaum, N. Razon, R. Kris, I. Lax, H. Soreq, N. Whittle, M. Waterfield, A. Ullrich, J. Schlessinger (1985)
Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin
Nature, 313
S. Cohen, R. Fava, S. Sawyer (1982)
Purification and characterization of epidermal growth factor receptor/protein kinase from normal mouse liver.
Proceedings of the National Academy of Sciences of the United States of America, 79 20
J Lu (2009)
195
Cancer Cell, 16
M. Scaltriti, F. Rojo, A. Ocaña, J. Anido, M. Guzman, J. Cortés, S. Cosimo, X. Matías-Guiu, S. Cajal, J. Arribas, J. Baselga (2007)
Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.
Journal of the National Cancer Institute, 99 8
W. Fiske, J. Tanksley, K. Nam, J. Goldenring, R. Slebos, D. Liebler, Amir Abtahi, Bonnie Fleur, G. Ayers, C. Lind, M. Washington, R. Coffey (2009)
Efficacy of Cetuximab in the Treatment of Ménétrier’s Disease
Science Translational Medicine, 1
D. Cunningham, Y. Humblet, S. Siena, D. Khayat, H. Bleiberg, A. Santoro, D. Bets, M. Mueser, A. Harstrick, C. Verslype, I. Chau, E. Cutsem (2004)
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.
The New England journal of medicine, 351 4
M. Gassmann, F. Casagranda, D. Orioli, H. Simon, Cary Lai, R. Klein, G. Lemke (1995)
Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor
Nature, 378
Y. Yarden, J. Schlessinger (1987)
Epidermal growth factor induces rapid, reversible aggregation of the purified epidermal growth factor receptor.
Biochemistry, 26 5
P Stephens (2004)
525
Nature, 431
Daniel Jones (2004)
Anticancer drugs: To the rescue?
Nature Reviews Drug Discovery, 3
J. Baselga, D. Tripathy, J. Mendelsohn, S. Baughman, C. Benz, L. Dantis, N. Sklarin, A. Seidman, C. Hudis, J. Moore, P. Rosen, T. Twaddell, I. Henderson, L. Norton (1996)
Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 14 3
D. Slamon, W. Godolphin, L. Jones, J. Holt, Steven Wong, D. Keith, W. Levin, S. Stuart, J. Udove, A. Ullrich, M. Press (1989)
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.
Science, 244 4905
Cori Bargmann, M. Hung, R. Weinberg (1986)
Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185
Cell, 45
S. Cohen (1972)
Epidermal growth factor
Bioscience Reports, 6
J. Paez, P. Jänne, Jeffrey Lee, Sean Tracy, H. Greulich, S. Gabriel, P. Herman, F. Kaye, N. Lindeman, T. Boggon, K. Naoki, H. Sasaki, Y. Fujii, M. Eck, W. Sellers, B. Johnson, M. Meyerson (2004)
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Science, 304
S. Cohen (1962)
Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the new-born animal.
The Journal of biological chemistry, 237
H. Masui, T. Kawamoto, J. Sato, B. Wolf, G. Sato, J. Mendelsohn (1984)
Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies.
Cancer research, 44 3
L. Mi, Chafen Lu, Zongli Li, N. Nishida, T. Walz, T. Springer (2011)
Simultaneous visualization of the extracellular and cytoplasmic domains of the epidermal growth factor receptor
Nature Structural &Molecular Biology, 18
Hyun-soo Cho, D. Leahy (2002)
Structure of the Extracellular Region of HER3 Reveals an Interdomain Tether
Science, 297
R. Hudziak, G. Lewis, M. Winget, B. Fendly, H. Shepard, Axel ULLRICHlt (1989)
p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor
Molecular and Cellular Biology, 9
F. Shi, S. Telesco, Yingting Liu, R. Radhakrishnan, M. Lemmon (2010)
ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation
Proceedings of the National Academy of Sciences, 107
Tadashi Yamamoto, S. Ikawa, T. Akiyama, K. Semba, N. Nomura, N. Miyajima, Toshiyuki Saito, K. Toyoshima (1986)
Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor
Nature, 319
D. Knighton, D. Cadena, J. Zheng, L. Eyck, S. Taylor, J. Sowadski, G. Gill (1993)
Structural features that specify tyrosine kinase activity deduced from homology modeling of the epidermal growth factor receptor.
Proceedings of the National Academy of Sciences of the United States of America, 90 11
W. Pao, V. Miller, K. Politi, Gregory Riely, R. Somwar, M. Zakowski, M. Kris, H. Varmus (2005)
Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
PLoS Medicine, 2
Q. Ryan, A. Ibrahim, M. Cohen, John Johnson, C. Ko, R. Sridhara, R. Justice, R. Pazdur (2008)
FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2.
The oncologist, 13 10
M. Kraus, N. Popescu, S. Amsbaugh, C. King (1987)
Overexpression of the EGF receptor‐related proto‐oncogene erbB‐2 in human mammary tumor cell lines by different molecular mechanisms.
The EMBO Journal, 6
M. Cohen, John Johnson, Yeh-Fong Chen, R. Sridhara, R. Pazdur (2005)
FDA drug approval summary: erlotinib (Tarceva) tablets.
The oncologist, 10 7
R. Nahta, Dihua Yu, M. Hung, G. Hortobagyi, F. Esteva (2006)
Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer
Nature Clinical Practice Oncology, 3
A. Schechter, M. Hung, Lalitha Vaidyanathan, R. Weinberg, T. Yang-Feng, U. Francke, A. Ullrich, L. Coussens (1985)
The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor.
Science, 229 4717
J. Bonner, P. Harari, J. Giralt, N. Azarnia, D. Shin, R. Cohen, Christopher Jones, R. Sur, D. Raben, J. Jassem, R. Ove, M. Kies, J. Baselga, H. Youssoufian, N. Amellal, E. Rowinsky, E. Rowinsky, K. Ang (2006)
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.
The New England journal of medicine, 354 6
J. Stelling, U. Sauer, Z. Szallasi, F. Doyle, J. Doyle (2004)
Robustness of Cellular Functions
Cell, 118
B. McInnes, Jannene McBride, N. Evans, David Lambert, A. Andrew (1999)
Emergence of Scaling in Random Networks
W. Holmes, M. Sliwkowski, R. Akita, W. Henzel, James Lee, John Park, D. Yansura, N. Abadi, H. Raab, G. Lewis, H. Shepard, W. Kuang, William Wood, D. Goeddel, R. Vandlen (1992)
Identification of Heregulin, a Specific Activator of p185erbB2
Science, 256
B. Kholodenko, J. Hancock, W. Kolch (2010)
Signalling ballet in space and time
Nature Reviews Molecular Cell Biology, 11
J. Drebin, V. Link, D. Stern, R. Weinberg, M. Greene (1985)
Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies
Cell, 41
H. Umezawa, M. Imoto, T. Sawa, K. Isshiki, N. Matsuda, T. Uchida, H. Iinuma, M. Hamada, T. Takeuchi (1986)
Studies on a new epidermal growth factor-receptor kinase inhibitor, erbstatin, produced by MH435-hF3.
The Journal of antibiotics, 39 1
I Niculescu-Duvaz (2010)
350
Curr. Opin. Mol. Ther., 12
Moshit Lindzen, Silvia Carvalho, A. Starr, N. Ben-Chetrit, C. Pradeep, W. Köstler, A. Rabinkov, S. Lavi, S. Bacus, Y. Yarden (2011)
A recombinant decoy comprising EGFR and ErbB-4 inhibits tumor growth and metastasis
Oncogene, 31
I. Amit, R. Wides, Y. Yarden (2007)
Evolvable signaling networks of receptor tyrosine kinases: relevance of robustness to malignancy and to cancer therapy
Molecular Systems Biology, 3
P. Yaish, A. Gazit, C. Gilon, A. Levitzki (1988)
Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors
Science, 242
AL Barabasi (1999)
509
Science, 286
Susumu Kobayashi, T. Boggon, Tajhal Dayaram, P. Jänne, O. Kocher, M. Meyerson, B. Johnson, M. Eck, D. Tenen, B. Halmos (2005)
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.
The New England journal of medicine, 352 8
B. Rexer, J. Engelman, C. Arteaga (2009)
Overcoming resistance to tyrosine kinase inhibitors: Lessons learned from cancer cells treated with EGFR antagonists
Cell Cycle, 8
M. Sliwkowski, G. Schaefer, R. Akita, J. Lofgren, V. Fitzpatrick, A. Nuijens, B. Fendly, R. Cerione, R. Vandlen, K. Carraway (1994)
Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin.
The Journal of biological chemistry, 269 20
F. Hendler, B. Ozanne (1984)
Human squamous cell lung cancers express increased epidermal growth factor receptors.
The Journal of clinical investigation, 74 2
Y. Soung, J. Lee, S. Kim, Young-Pil Wang, K. Jo, S. Moon, W. Park, S. Nam, Jung Lee, N. Yoo, S. Lee (2006)
Somatic mutations of the ERBB4 kinase domain in human cancers
International Journal of Cancer, 118
C. King, M. Kraus, S. Aaronson (1985)
Amplification of a novel v-erbB-related gene in a human mammary carcinoma.
Science, 229 4717
IB Weinstein (2002)
Cancer. Addiction to oncogenes- the Achilles heal of cancer
Science, 297
J. Baselga, J. Cortés, Sung-Bae Kim, S. Im, R. Hegg, Y. Im, L. Roman, J. Pedrini, T. Pieńkowski, A. Knott, E. Clark, M. Benyunes, G. Ross, S. Swain (2012)
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.
The New England journal of medicine, 366 2
H. Kitano (2008)
Biological robustness
Nature Reviews Genetics, 5
G. Levkowitz, H. Waterman, E. Zamir, Z. Kam, S. Oved, W. Langdon, L. Beguinot, B. Geiger, Y. Yarden (1998)
c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor.
Genes & development, 12 23
B. Schoeberl, Claudia Eichler-Jonsson, E. Gilles, G. Müller (2002)
Computational modeling of the dynamics of the MAP kinase cascade activated by surface and internalized EGF receptors
Nature Biotechnology, 20
J. Downward, Y. Yarden, E. Mayes, G. Scrace, N. Totty, P. Stockwell, A. Ullrich, J. Schlessinger, M. Waterfield (1984)
Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences
Nature, 307
Todd Prickett, Neena Agrawal, Xiaomu Wei, K. Yates, Jimmy Lin, J. Wunderlich, J. Cronin, P. Cruz, S. Rosenberg, Yardena Samuels (2009)
Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4
Nature Genetics, 41
M. Vijver, J. Peterse, W. Mooi, Peter Wisman, Job Lomans, O. Dalesio, R. Nusse (1988)
Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer.
The New England journal of medicine, 319 19
B. Kholodenko, O. Demin, G. Moehren, J. Hoek (1999)
Quantification of Short Term Signaling by the Epidermal Growth Factor Receptor*
The Journal of Biological Chemistry, 274
L. Coussens, Teresa Yang−Feng, Y. Liao, E. Chen, A. Gray, J. Mcgrath, P. Seeburg, T. Libermann, J. Schlessinger, U. Francke, A. Levinson, A. Ullrich (1985)
Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene.
Science, 230 4730
M. Franklin, K. Carey, F. Vajdos, D. Leahy, A. Vos, M. Sliwkowski (2004)
Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex.
Cancer cell, 5 4
TJ Lynch (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
N. Engl. J. Med., 350
E. Peles, S. Bacus, R. Koski, Hsieng Lu, D. Wen, Steven Ogden, R. Levy, Y. Yarden (1992)
Isolation of the Neu HER-2 stimulatory ligand: A 44 kd glycoprotein that induces differentiation of mammary tumor cells
Cell, 69
I. Dikič, S. Giordano (2003)
Negative receptor signalling.
Current opinion in cell biology, 15 2
M. Freeman (2000)
Feedback control of intercellular signalling in development
Nature, 408
I. Niculescu-Duvaz (2010)
Trastuzumab emtansine, an antibody-drug conjugate for the treatment of HER2+ metastatic breast cancer.
Current opinion in molecular therapeutics, 12 3
M. Hung, D. Yan, Xiaoyan Zhao (1989)
Amplification of the proto-neu oncogene facilitates oncogenic activation by a single point mutation.
Proceedings of the National Academy of Sciences of the United States of America, 86 8
Charles Geyer, J. Forster, D. Lindquist, Stephen Chan, C. Romieu, T. Pieńkowski, A. Jagiełło-Gruszfeld, J. Crown, Arlene Chan, Bella Kaufman, Dimosthenis Skarlos, M. Campone, Neville Davidson, Mark Berger, C. Oliva, S. Rubin, S. Stein, David Cameron (2006)
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
The New England journal of medicine, 355 26
H. Kitano (2002)
Systems Biology: A Brief Overview
Science, 295
V. Miller, M. Kris, N. Shah, J. Patel, C. Azzoli, Jorge Gomez, L. Krug, W. Pao, N. Rizvi, B. Pizzo, L. Tyson, E. Venkatraman, L. Ben-Porat, N. Memoli, M. Zakowski, V. Rusch, R. Heelan (2004)
Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 22 6
K. Semba (1985)
A v-erbB-related protooncogene, c-erb-B-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma
, 82
Na Li, H. Nguyen, M. Byrom, A. Ellington (2011)
Inhibition of Cell Proliferation by an Anti-EGFR Aptamer
PLoS ONE, 6
N. Jura, Yibing Shan, Xiaoxian Cao, D. Shaw, J. Kuriyan (2009)
Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3
Proceedings of the National Academy of Sciences, 106
L. Klapper, Stefanie Glathe, N. Vaisman, N. Hynes, G. Andrews, M. Sela, Y. Yarden (1999)
The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors.
Proceedings of the National Academy of Sciences of the United States of America, 96 9
Y. Yarden, A. Ullrich (1988)
Growth factor receptor tyrosine kinases.
Annual review of biochemistry, 57
G. Schaefer, Lauric Haber, Lisa Crocker, S. Shia, Lily Shao, D. Dowbenko, K. Totpal, A. Wong, Chingwei Lee, S. Stawicki, Robyn Clark, Carter Fields, Gail Phillips, R. Prell, D. Danilenko, Y. Franke, J. Stephan, Jiyoung Hwang, Yan Wu, J. Bostrom, M. Sliwkowski, G. Fuh, C. Eigenbrot (2011)
A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies.
Cancer cell, 20 4
S. Lee-Hoeflich, Lisa Crocker, E. Yao, Thinh Pham, Xander Munroe, K. Hoeflich, M. Sliwkowski, H. Stern (2008)
A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy.
Cancer research, 68 14
Y. Yarden, R. Weinberg (1989)
Experimental approaches to hypothetical hormones: detection of a candidate ligand of the neu protooncogene.
Proceedings of the National Academy of Sciences of the United States of America, 86 9
Y Yarden (1985)
23
Ciba Found. Symp., 116
A. Schreiber, I. Lax, Y. Yarden, Z. Eshhar, J. Schlessinger (1981)
Monoclonal antibodies against receptor for epidermal growth factor induce early and delayed effects of epidermal growth factor.
Proceedings of the National Academy of Sciences of the United States of America, 78 12
JT Garrett, CL Arteaga (2011)
Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications
Cancer Biol. Ther., 11
E. Pettersen, Thomas Goddard, Conrad Huang, Gregory Couch, Daniel Greenblatt, E. Meng, T. Ferrin (2004)
UCSF Chimera—A visualization system for exploratory research and analysis
Journal of Computational Chemistry, 25
E Peles (1992)
Isolation of the neu/HER-2 stimulatory ligand: a 44 kd glycoprotein that induces differentiation of mammary tumor cells
Cell, 69
M. Brewer, Sung-Hee Choi, Diego Alvarado, K. Moravcevic, A. Pozzi, M. Lemmon, G. Carpenter (2009)
The juxtamembrane region of the EGF receptor functions as an activation domain.
Molecular cell, 34 6
RM Hudziak (1989)
1165
Mol. Cell. Biol., 9
CR Savage Jr (1972)
7612
J. Biol. Chem., 247
Moshit Lindzen, S. Lavi, O. Leitner, Y. Yarden (2010)
Tailored cancer immunotherapy using combinations of chemotherapy and a mixture of antibodies against EGF-receptor ligands
Proceedings of the National Academy of Sciences, 107
N. Zandwijk (2006)
Faculty Opinions recommendation of Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer).
E. Aboud-Pirak, E. Hurwitz, M. Pirak, F. Bellot, J. Schlessinger, M. Sela (1988)
Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice.
Journal of the National Cancer Institute, 80 20
P. Fiore, J. Pierce, M. Kraus, O. Segatto, C. King, S. Aaronson (1987)
erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells.
Science, 237 4811
M Kirschner, J Gerhart (1998)
Evolvability
Proc. Natl Acad. Sci. USA, 95
Y. Kokai, J. Myers, T. Wada, V. Brown, C. LeVea, James Davis, K. Dobashi, M. Greene (1989)
Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts
Cell, 58
M. Cohen, Grant Williams, R. Sridhara, Gang Chen, R. Pazdur (2003)
FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets.
The oncologist, 8 4
R. Clynes, Terri Towers, L. Presta, J. Ravetch (2000)
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Nature Medicine, 6
M. Waterfield, G. Scrace, N. Whittle, P. Stroobant, A. Johnsson, Å. Wasteson, B. Westermark, C. Heldin, J. Huang, T. Deuel (1983)
Platelet-derived growth factor is structurally related to the putative transforming protein p28sis of simian sarcoma virus
Nature, 304
P. Carter, L. Presta, C. Gorman, J. Ridgway, D. Henner, Wai Wong, A. Rowland, C. Kotts, M. Carver, H. Shepard (1992)
Humanization of an anti-p185HER2 antibody for human cancer therapy.
Proceedings of the National Academy of Sciences of the United States of America, 89
Andrew Tatem, Carlos Guerra, Peter Atkinson, Simon Hay (2004)
Athletics: Momentous sprint at the 2156 Olympics?
Nature, 431
W. Xia, S. Bacus, P. Hegde, I. Husain, J. Strum, Lei-hua Liu, G. Paulazzo, L. Lyass, P. Trusk, Jason Hill, Jennifer Harris, N. Spector (2006)
A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer
, 103
A. Ullrich, L. Coussens, J. Hayflick, T. Dull, A. Gray, A. Tam, J. Lee, Y. Yarden, T. Libermann, J. Schlessinger, J. Downward, E. Mayes, N. Whittle, M. Waterfield, P. Seeburg (1984)
Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells
Nature, 309
(2009)
14-3-3ζ Cooperates with ErbB2 to promote ductal carcinoma in situ progression to invasive breast cancer by inducing epithelial-mesenchymal transition
N. Thatcher, A. Chang, P. Parikh, J. Pereira, T. Ciuleanu, J. Pawel, S. Thongprasert, E. Tan, K. Pemberton, V. Archer, K. Carroll (2005)
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
The Lancet, 366
K. Carraway, L. Cantley (1994)
A neu acquaintance for ErbB3 and ErbB4: A role for receptor heterodimerization in growth signaling
Cell, 78
G. Carpenter, S. Cohen (1976)
125I-labeled human epidermal growth factor. Binding, internalization, and degradation in human fibroblasts
The Journal of Cell Biology, 71
C. Greenfield, I. Hiles, Michael Waterfield, M. Federwisch, A. Wollmer, Tom Blundell, Neil McDonald (1989)
Epidermal growth factor binding induces a conformational change in the external domain of its receptor.
The EMBO Journal, 8
Andrew Barker, Keith Gibson, W. Grundy, A. Godfrey, Jeffrey Barlow, Mark Healy, J. Woodburn, Susan Ashton, Brenda Curry, Lynn Scarlett, Lianne Henthorn, Laura Richards (2001)
Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer.
Bioorganic & medicinal chemistry letters, 11 14
D. Peng, Z. Fan, Yang Lu, T. Deblasio, H. Scher, H. Scher, J. Mendelsohn (1996)
Anti-epidermal growth factor receptor monoclonal antibody 225 up-regulates p27KIP1 and induces G1 arrest in prostatic cancer cell line DU145.
Cancer research, 56 16
D. Meyer, C. Birchmeier (1995)
Multiple essential functions of neuregulin in development
Nature, 378
D. Graus‐Porta, R. Beerli, J. Daly, N. Hynes (1997)
ErbB‐2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling
The EMBO Journal, 16
M. Sporn, G. Todaro (1980)
Autocrine secretion and malignant transformation of cells.
The New England journal of medicine, 303 15
GN Hortobagyi (2005)
1734
N. Engl. J. Med., 353
S. Telesco, Andrew Shih, Fei Jia, R. Radhakrishnan (2011)
A multiscale modeling approach to investigate molecular mechanisms of pseudokinase activation and drug resistance in the HER3/ErbB3 receptor tyrosine kinase signaling network.
Molecular bioSystems, 7 6
A. Schechter, D. Stern, Lalitha Vaidyanathan, S. Decker, J. Drebin, M. Greene, R. Weinberg (1984)
The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen
Nature, 312
C. Wallasch, F. Weiss, G. Niederfellner, B. Jallal, W. Issing, A. Ullrich (1995)
Heregulin‐dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3.
The EMBO Journal, 14
V. Pollack, D. Savage, Deborah Baker, Konstantinos Tsaparikos, D. Sloan, J. Moyer, E. Barbacci, L. Pustilnik, T. Smolarek, John Davis, M. Vaidya, L. Arnold, J. Doty, K. Iwata, M. Morin (1999)
Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice.
The Journal of pharmacology and experimental therapeutics, 291 2
R. Pinkas-Kramarski, R. Eilam, I. Alroy, G. Levkowitz, P. Lonai, Y. Yarden (1997)
Differential expression of NDF/neuregulin receptors ErbB-3 and ErbB-4 and involvement in inhibition of neuronal differentiation
Oncogene, 15
Thomas Holbro, R. Beerli, Francisca Maurer, M. Koziczak, Carlos Barbas, N. Hynes (2003)
The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation
Proceedings of the National Academy of Sciences of the United States of America, 100
E. Peles, R. Ben-Levy, E. Tzahar, Naili Liu, '. DuanzhiWen, Y. Yarden (1993)
Cell‐type specific interaction of Neu differentiation factor (NDF/heregulin) with Neu/HER‐2 suggests complex ligand‐receptor relationships.
The EMBO Journal, 12
M. Fukuoka, S. Yano, G. Giaccone, T. Tamura, K. Nakagawa, J. Douillard, Y. Nishiwaki, J. Vansteenkiste, S. Kudoh, D. Rischin, R. Eek, T. Horai, K. Noda, I. Takata, E. Smit, S. Averbuch, A. Macleod, A. Feyereislova, R. Dong, J. Baselga (2003)
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 21 12
J. Sato, T. Kawamoto, A. Le, J. Mendelsohn, J. Polikoff, G. Sato (1983)
Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors.
Molecular biology & medicine, 1 5
Y. Yarden, M. Sliwkowski (2001)
Untangling the ErbB signalling network
Nature Reviews Molecular Cell Biology, 2
D. Wen, E. Peles, R. Cupples, S. Suggs, S. Bacus, Yi Luo, Geraldine Trail, Sylvia Hu, S. Silbiger, R. Levy, R. Koski, Hsieng Lu, Y. Yarden (1992)
Neu differentiation factor: A transmembrane glycoprotein containing an EGF domain and an immunoglobulin homology unit
Cell, 69
Allan Levi, R. Bunge, J. Lofgren, L. Meima, Franz Hefti, K. Nikolics, M. Sliwkowski (1995)
The influence of heregulins on human Schwann cell proliferation
, 15
Rina Goldman, R. Levy, E. Peles, Y. Yarden (1990)
Heterodimerization of the erbB-1 and erbB-2 receptors in human breast carcinoma cells: a mechanism for receptor transregulation.
Biochemistry, 29 50
M Alimandi (1995)
1813
Oncogene, 10
P Stephens (2004)
Lung cancer: intragenic ERBB2 kinase mutations in tumours
Nature, 431
K. Yonesaka, K. Zejnullahu, I. Okamoto, T. Satoh, F. Cappuzzo, J. Souglakos, D. Ercan, Andrew Rogers, M. Roncalli, M. Takeda, Y. Fujisaka, Juliet Philips, Toshio Shimizu, O. Maenishi, Y. Cho, J. Sun, A. Destro, K. Taira, K. Takeda, T. Okabe, Jeffrey Swanson, H. Itoh, M. Takada, E. Lifshits, K. Okuno, J. Engelman, R. Shivdasani, K. Nishio, M. Fukuoka, M. Varella-Garcia, K. Nakagawa, P. Jänne (2011)
Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab
Science Translational Medicine, 3
T. Garrett, N. Mckern, M. Lou, T. Elleman, T. Adams, G. Lovrecz, Hong-Jian Zhu, F. Walker, M. Frenkel, P. Hoyne, R. Jorissen, E. Nice, A. Burgess, C. Ward (2002)
Crystal Structure of a Truncated Epidermal Growth Factor Receptor Extracellular Domain Bound to Transforming Growth Factor α
Cell, 110
J. Stagg, S. Loi, U. Divisekera, S. Ngiow, Hélène Duret, H. Yagita, M. Teng, M. Smyth (2011)
Anti–ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti–PD-1 or anti-CD137 mAb therapy
Proceedings of the National Academy of Sciences, 108
E. Tzahar, H. Waterman, Xiomei Chen, G. Levkowitz, D. Karunagaran, S. Lavi, B. Ratzkin, Y. Yarden (1996)
A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor
Molecular and Cellular Biology, 16
D. Slamon, G. Clark, S. Wong, W. Levin, A. Ullrich, W. McGuire (1987)
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.
Science, 235 4785
D Peng (1996)
3666
Cancer Res., 56
Yoichi Nagata, K. Lan, Xiaoyan Zhou, M. Tan, F. Esteva, A. Sahin, K. Klos, Ping Li, B. Monia, Nina Nguyen, G. Hortobagyi, M. Hung, Dihua Yu (2004)
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.
Cancer cell, 6 2
M. Kraus, W. Issing, T. Miki, Nicholas POPESCUt, S. Aaronson (1989)
Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors.
Proceedings of the National Academy of Sciences of the United States of America, 86 23
F. Haj, P. Verveer, A. Squire, B. Neel, P. Bastiaens (2002)
Imaging Sites of Receptor Dephosphorylation by PTP1B on the Surface of the Endoplasmic Reticulum
Science, 295
K. Berns, H. Horlings, B. Hennessy, M. Madiredjo, E. Hijmans, K. Beelen, S. Linn, A. González-Angulo, K. Stemke‐Hale, M. Hauptmann, R. Beijersbergen, G. Mills, M. Vijver, R. Bernards (2007)
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.
Cancer cell, 12 4
SaeGwang Park, Zhujun Jiang, Eric Mortenson, Liufu Deng, Olga Radkevich-Brown, Xuanming Yang, H. Sattar, Yang Wang, N. Brown, M. Greene, Yang Liu, Jie Tang, Shengdian Wang, yang-xin fu (2010)
The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity.
Cancer cell, 18 2
S. Cohen, G. Carpenter (1975)
Human epidermal growth factor: isolation and chemical and biological properties.
Proceedings of the National Academy of Sciences of the United States of America, 72 4
A. Lièvre, J. Bachet, D. Corre, V. Boige, B. Landi, J. Emile, J. Côté, G. Tomasic, C. Penna, M. Ducreux, P. Rougier, F. Penault-Llorca, P. Laurent-Puig (2006)
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.
Cancer research, 66 8
S. Bouyain, P. Longo, Shiqing Li, K. Ferguson, D. Leahy (2005)
The extracellular region of ErbB4 adopts a tethered conformation in the absence of ligand.
Proceedings of the National Academy of Sciences of the United States of America, 102 42
N. Hynes, Gwen Macdonald (2009)
ErbB receptors and signaling pathways in cancer.
Current opinion in cell biology, 21 2
D. Karunagaran, E. Tzahar, R. Beerli, Xiaomei Chen, D. Graus‐Porta, B. Ratzkin, R. Seger, N. Hynes, '. YosefYardenl (1996)
ErbB‐2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer.
The EMBO Journal, 15
Kanae Oda, Yukiko Matsuoka, Akira Funahashi, Hiroaki Kitano (2005)
A comprehensive pathway map of epidermal growth factor receptor signaling
Molecular Systems Biology, 1
DW Rusnak (2001)
7196
Cancer Res., 61
J. Engelman, K. Zejnullahu, T. Mitsudomi, Youngchul Song, Courtney Hyland, Joon-Oh Park, N. Lindeman, Christopher-Michael Gale, Xiaojun Zhao, J. Christensen, T. Kosaka, A. Holmes, A. Rogers, F. Cappuzzo, T. Mok, Charles Lee, B. Johnson, L. Cantley, P. Jänne (2007)
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Science, 316
E. Bocharov, K. Mineev, P. Volynsky, Y. Ermolyuk, E. Tkach, A. Sobol, V. Chupin, M. Kirpichnikov, R. Efremov, A. Arseniev (2008)
Spatial Structure of the Dimeric Transmembrane Domain of the Growth Factor Receptor ErbB2 Presumably Corresponding to the Receptor Active State*
Journal of Biological Chemistry, 283
H. Ogiso, R. Ishitani, O. Nureki, S. Fukai, M. Yamanaka, Jae-Hoon Kim, K. Saito, A. Sakamoto, M. Inoue, M. Shirouzu, S. Yokoyama (2002)
Crystal Structure of the Complex of Human Epidermal Growth Factor and Receptor Extracellular Domains
Cell, 110
Raffaella Sordella, D. Bell, D. Haber, J. Settleman (2004)
Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways
Science, 305
C. Montagut, A. Dalmases, B. Bellosillo, M. Crespo, S. Pairet, M. Iglesias, M. Salido, M. Gallén, S. Marsters, S. Tsai, A. Minoche, S. Seshagiri, S. Serrano, H. Himmelbauer, J. Bellmunt, A. Rovira, J. Settleman, F. Bosch, J. Albanell (2012)
Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer
Nature Medicine, 18
D. Rusnak, K. Affleck, S. Cockerill, C. Stubberfield, Robert Harris, M. Page, K. Smith, S. Guntrip, M. Carter, R. Shaw, A. Jowett, J. Stables, P. Topley, E. Wood, P. Brignola, S. Kadwell, B. Reep, R. Mullin, K. Alligood, B. Keith, R. Crosby, D. Murray, W. Knight, T. Gilmer, K. Lackey (2001)
The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer.
Cancer research, 61 19
C. Savage, Tadashi Inagami, S. Cohen (1972)
The primary structure of epidermal growth factor.
The Journal of biological chemistry, 247 23
D. Riese, M. Tom, van, Raaij, G. Plowman, G. Andrews, D. Stern (1995)
The cellular response to neuregulins is governed by complex interactions of the erbB receptor family
Molecular and Cellular Biology, 15
K. Semba, N. Kamata, K. Toyoshima, Tadashi Yamamoto (1985)
A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma.
Proceedings of the National Academy of Sciences of the United States of America, 82 19
Hyun-soo Cho, K. Mason, K. Ramyar, A. Stanley, S. Gabelli, D. Denney, D. Leahy (2003)
Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab
Nature, 421
TJ Lynch (2004)
2129
N. Engl. J. Med., 350
Xuewu Zhang, Jodi Gureasko, Kui Shen, P. Cole, J. Kuriyan (2006)
An Allosteric Mechanism for Activation of the Kinase Domain of Epidermal Growth Factor Receptor
Cell, 125
S. Khambata-Ford, C. Garrett, N. Meropol, M. Basik, C. Harbison, Shujian Wu, T. Wong, Xin Huang, C. Takimoto, A. Godwin, B. Tan, S. Krishnamurthi, H. Burris, E. Poplin, M. Hidalgo, J. Baselga, E. Clark, D. Mauro (2007)
Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 22
Loredana Fiorentino, C. Pertica, Monia Fiorini, C. Talora, M. Crescenzi, L. Castellani, S. Alemà, Piero Benedetti, O. Segatto (2000)
Inhibition of ErbB-2 Mitogenic and Transforming Activity by RALT, a Mitogen-Induced Signal Transducer Which Binds to the ErbB-2 Kinase Domain
Molecular and Cellular Biology, 20
N. Spector, W. Xia, H. Burris, H. Hurwitz, E. Dees, A. Dowlati, B. O'Neil, B. Overmoyer, P. Marcom, K. Blackwell, Deborah Smith, K. Koch, A. Stead, S. Mangum, M. Ellis, Lei-hua Liu, A. Man, T. Bremer, Jennifer Harris, S. Bacus (2005)
Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 11
N. Jura, Nicholas Endres, K. Engel, S. Deindl, Rahul Das, M. Lamers, D. Wemmer, Xuewu Zhang, J. Kuriyan (2009)
Mechanism for Activation of the EGF Receptor Catalytic Domain by the Juxtamembrane Segment
Cell, 137
D. Meyer, C. Birchmeier (1994)
Distinct isoforms of neuregulin are expressed in mesenchymal and neuronal cells during mouse development.
Proceedings of the National Academy of Sciences of the United States of America, 91
T. Libermann, N. Razon, A. Bartal, Y. Yarden, J. Schlessinger, H. Soreq (1984)
Expression of epidermal growth factor receptors in human brain tumors.
Cancer research, 44 2
K. Ferguson, M. Berger, J. Mendrola, Hyun-soo Cho, D. Leahy, M. Lemmon (2003)
EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization.
Molecular cell, 11 2
G. Plowman, J. Culouscou, G. Whitney, Janell Green, G. Carlton, L. Foy, M. Neubauer, M. Shoyab (1993)
Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family.
Proceedings of the National Academy of Sciences of the United States of America, 90
A. Roberts, L. Lamb, D. Newton, M. Sporn, DE JOSEPHE., LARCOt, George TODAROt (1980)
Transforming growth factors: isolation of polypeptides from virally and chemically transformed cells by acid/ethanol extraction.
Proceedings of the National Academy of Sciences of the United States of America, 77 6
MX Sliwkowski (1994)
14661
J. Biol. Chem., 269
D. Slamon, B. Leyland-Jones, Steven Shak, Hank Fuchs, Virginia Paton, A. Bajamonde, Thomas Fleming, W. Eiermann, Janet Wolter, M. Pegram, J. Baselga, Larry Norton (2001)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
The New England journal of medicine, 344 11
H Masui (1984)
1002
Cancer Res., 44
B. Schoeberl, A. Faber, Danan Li, M. Liang, K. Crosby, M. Onsum, O. Burenkova, E. Pace, Z. Walton, L. Nie, Aaron Fulgham, Youngchul Song, U. Nielsen, J. Engelman, Kwok-kin Wong (2010)
An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation.
Cancer research, 70 6
JD Sato (1983)
511
Mol. Biol. Med., 1
G Carpenter (1979)
193
Annu. Rev. Biochem., 48
STANLEYCOHENANDRITALEVI-MONTALCINI (2006)
Purification and Properties of a Nerve Growth-promoting Factor Isolated from Mouse Sarcoma 180 *
G Carpenter, S Cohen (1979)
Epidermal growth factor
Annu. Rev. Biochem., 48
C. Scher, G. Todaro (1971)
Selective growth of human neoplastic cells in medium lacking serum growth factor.
Experimental cell research, 68 2
S. Benvenuti, A. Sartore-Bianchi, F. Nicolantonio, C. Zanon, M. Moroni, S. Veronese, S. Siena, A. Bardelli (2007)
Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.
Cancer research, 67 6
M Kirschner (1998)
8420
Proc. Natl Acad. Sci. USA, 95
J. Garrett, C. Arteaga (2011)
Resistance to HER2-directed antibodies and tyrosine kinase inhibitors
Cancer Biology & Therapy, 11
Shiaw-Yih Lin, K. Makino, W. Xia, A. Matin, Y. Wen, K. Kwong, L. Bourguignon, M. Hung (2001)
Nuclear localization of EGF receptor and its potential new role as a transcription factor
Nature Cell Biology, 3
W. Schulze, Lei Deng, M. Mann (2005)
Phosphotyrosine interactome of the ErbB-receptor kinase family
Molecular Systems Biology, 1
K. Blackwell, H. Burstein, A. Storniolo, H. Rugo, G. Sledge, M. Koehler, C. Ellis, M. Casey, S. Vukelja, J. Bischoff, J. Baselga, J. O’Shaughnessy (2010)
Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 7
P. Guy, J. Platko, Lewis CANTLEYt, R. Cerione, K. IIItt (1994)
Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity.
Proceedings of the National Academy of Sciences of the United States of America, 91 17
R. Hudziak, J. Schlessinger, A. Ullrich (1987)
Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells.
Proceedings of the National Academy of Sciences of the United States of America, 84 20
Li Liu, J. Greger, Hong Shi, Yuan Liu, J. Greshock, R. Annan, W. Halsey, G. Sathe, Anne-Marie Martin, T. Gilmer (2009)
Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL.
Cancer research, 69 17
J. Baselga, S. Swain (2009)
Novel anticancer targets: revisiting ERBB2 and discovering ERBB3
Nature Reviews Cancer, 9
和田卓郎 (1990)
Intermolecular association of the p185neu protein and EGF receptor modulates EGF receptor function
I. Amit, A. Citri, T. Shay, Yiling Lu, M. Katz, Fan Zhang, G. Tarcic, D. Siwak, John Lahad, J. Jacob-Hirsch, N. Amariglio, N. Vaisman, E. Segal, G. Rechavi, U. Alon, G. Mills, E. Domany, Y. Yarden (2007)
A module of negative feedback regulators defines growth factor signaling
Nature Genetics, 39
Chang-Yuan Ni, M. Murphy, T. Golde, G. Carpenter (2001)
γ-Secretase Cleavage and Nuclear Localization of ErbB-4 Receptor Tyrosine Kinase
Science, 294
L. Valiant (2009)
Evolvability
Electron. Colloquium Comput. Complex., TR06
S. Modi, A. Stopeck, H. Linden, D. Solit, S. Chandarlapaty, N. Rosen, G. D’Andrea, M. Dickler, M. Moynahan, S. Sugarman, Weining Ma, S. Patil, L. Norton, A. Hannah, C. Hudis (2011)
HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab
Clinical Cancer Research, 17
R. Avraham, Y. Yarden (2011)
Feedback regulation of EGFR signalling: decision making by early and delayed loops
Nature Reviews Molecular Cell Biology, 12
N. Sergina, Megan Rausch, Donghui Wang, Jimmy Blair, B. Hann, K. Shokat, M. Moasser (2007)
Escape from HER family tyrosine kinase inhibitor therapy by the kinase inactive HER3
Nature, 445
G. Plowman, G. Whitney, M. Neubauer, Janell Green, V. McDonald, G. Todaro, M. Shoyab, Oncogen (1990)
Molecular cloning and expression of an additional epidermal growth factor receptor-related gene.
Proceedings of the National Academy of Sciences of the United States of America, 87 13
Cori Bargmann, M. Hung, R. Weinberg (1986)
The neu oncogene encodes an epidermal growth factor receptor-related protein
Nature, 319
N. Sugawa, A. Ekstrand, C. James, V. Collins (1990)
Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas.
Proceedings of the National Academy of Sciences of the United States of America, 87
G. Todaro, C. Fryling, J. Larco (1980)
Transforming growth factors produced by certain human tumor cells: polypeptides that interact with epidermal growth factor receptors.
Proceedings of the National Academy of Sciences of the United States of America, 77 9
W. Pao, V. Miller, M. Zakowski, J. Doherty, K. Politi, I. Sarkaria, Bhuvanesh Singh, R. Heelan, V. Rusch, L. Fulton, E. Mardis, Doris Kupfer, R. Wilson, M. Kris, H. Varmus (2004)
EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.
Proceedings of the National Academy of Sciences of the United States of America, 101 36
F. Reynolds, G. Todaro, C. Fryling, J. Stephenson (1981)
Human transforming growth factors induce tyrosine phosphorylation of EGF receptors
Nature, 292
J. Baselga (2001)
The EGFR as a target for anticancer therapy--focus on cetuximab.
European journal of cancer, 37 Suppl 4
T. Hunter, Jonathan Cooper (1981)
Epidermal growth factor induces rapid tyrosine phosphorylation of proteins in A431 human tumor cells
Cell, 24
I. Weinstein (2002)
Addiction to Oncogenes--the Achilles Heal of Cancer
Science, 297

Publisher: Springer Journals
Subject: Biomedicine; Biomedicine, general; Cancer Research
ISSN: 1474-175X
eISSN: 1474-1768
DOI: 10.1038/nrc3309
Publisher site: See Article on Publisher Site

Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

The ERBB network: at last, cancer therapy meets systems biology

The ERBB network: at last, cancer therapy meets systems biology

Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

The ERBB network: at last, cancer therapy meets systems biology

The ERBB network: at last, cancer therapy meets systems biology

References (212)

Abstract

Journal

Recommended Articles

There are no references for this article.

Our policy towards the use of cookies